



Testimony of Sarah Calder, MaineHealth
In Opposition to LD 1001, “An Act to Prohibit Medical Providers and Certain Others from Reporting Prescribed Medication-assisted Treatment of Parents to Child Protective Services” and
LD 1006, “An Act to Allow Testing of Pregnant Persons for Drugs Directly Before and After Childbirth”
March 27, 2025

Senator Ingwersen, Representative Meyer and distinguished members of the Joint Standing Committee on Health and Human Services, I am Sarah Calder, Senior Government Affairs Director at MaineHealth, and I am here to express concerns with both LD 1001, “An Act to Prohibit Medical Providers and Certain Others from Reporting Prescribed Medication-assisted Treatment of Parents to Child Protective Services” and LD 1006, “An Act to Allow Testing of Pregnant Persons for Drugs Directly Before and After Childbirth.”

MaineHealth is an integrated non-profit health care system that provides a continuum of health care services to communities throughout Maine and New Hampshire. Every day, our over 24,000 care team members support our vision of “Working Together so Our Communities are the Healthiest in America” by providing a range of services from primary and specialty physician services to a continuum of behavioral health care services, community and tertiary hospital care, home health care and a lab.

With regards to LD 1001, this is very similar to the conversation that this Committee had regarding LD 156, An Act to Improve Notifications Related to Substance-exposed Infants. In that hearing, the Department of Health and Human Services agreed to convene stakeholders to develop recommendations that both comply with federal Child Abuse Prevention and Treatment Act (CAPTA) and support pregnant women and their newborns. Our first meeting is April 2. With that said, we would urge you to vote Ought Not to Pass on LD 1001 and allow the stakeholders to meet and develop recommendations and use LD 156 as a vehicle for those recommendations.

With regards to LD 1006, health care providers are already able to perform a blood test with the pregnant woman’s consent. We believe, however, that the intent behind this legislation is, again, related to the issue of substance exposed infants, and we would urge the Committee to vote Ought Not to Pass on LD 1006 and allow the stakeholders to address this issue through the LD 156 work group.

Thank you for your time and consideration and I would be happy to answer any questions that you may have.